You have full text access to this OnlineOpen article

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

  1. S. Nair1,
  2. A. M. Diehl2,
  3. M. Wiseman1,
  4. G. H. Farr Jr3,
  5. R. P. Perrillo1

Article first published online: 14 JUN 2004

DOI: 10.1111/j.1365-2036.2004.02025.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 20, Issue 1, pages 23–28, July 2004

Additional Information

How to Cite

Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H. and Perrillo, R. P. (2004), Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology & Therapeutics, 20: 23–28. doi: 10.1111/j.1365-2036.2004.02025.x

Author Information

  1. 1

    Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LA, USA

  2. 2

    Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

  3. 3

    Section of Pathology, Ochsner Clinic Foundation, New Orleans, LA, USA

*Dr S. Nair, Ochsner Clinic Foundation, Div Abdominal Organ Transplantation, BH 309, 1514 Jefferson Hwy, New Orleans, LA 70121, USA. E-mail: snair@ochsner.org

Publication History

  1. Issue published online: 14 JUN 2004
  2. Article first published online: 14 JUN 2004
  3. Accepted for publication 2 May 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (82K)

Summary

Background : Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease.

Aim : A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease.

Methods : In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology.

Results : Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis.

Conclusion : Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

View Full Article (HTML) Get PDF (82K)